[PDF]Help with a big problem - Rackcdn.comc398534.r34.cf1.rackcdn.com/...
3 downloads
209 Views
200KB Size
Philips Healthcare is part of Royal Philips Electronics
Prevalence of OSA • As many as 5 to 10 percent of adults in the U.S. have OSA.1,2 • Nine percent of men and four percent of women have an apnea hypopnea index (AHI) greater than 15 (moderate OSA). • Prevalence of OSA is higher in the following ethnic groups3: – Asian – Hispanic women – African-American • 85 to 90 percent of people within the U.S. who may have OSA have not been identified.1
Many of the 20 million people in the U.S. suspected of having OSA may have an increased risk for other serious health conditions.
How to reach us www.philips.com/healthcare Fax: +31 40 27 64 887 Asia +852 2821 5888 Europe, Middle East,Africa +31 40 27 87246 Latin America +55 11 2125 0764
Philips Respironics 1010 Murry Ridge Lane Murrysville, PA 15668 Customer Service +1 724 387 4000 800 345 6443 (toll free) Respironics Europe, Middle East,Africa +33 1 47 52 30 00 Respironics Asia Pacific +852 3194 2280 www.philips.com/respironics
North America +1 425 487 7000 800 285 5585 (toll free, US only)
Cardiovascular disease
Stroke
Diabetes
For more information about Obstructive Sleep Apnea visit: www.sleepapnea.com
OSA 20 M overall
Help with a big problem How to screen for Obstructive Sleep Apnea (OSA) in your obese patients
Atrial fibrillation
Hypertension
© 2009 Koninklijke Philips Electronics N.V. All rights are reserved. 1 Young,T., et
al., NEJM 1993;328:1230-1235
2 Young,T., et
al., AJRCCM 2002;165:1217-1239
3 O’Connor, et
al., Sleep 2003;26(1):74-79
4 Hiestand, D.M., et
al., Chest 2006;130:780-786
Philips Healthcare reserves the right to make changes in specifications and/or to discontinue any product at any time without notice or obligation and will not be liable for any consequences resulting from the use of this publication. Geyer SB 1/22/09 MCI 4102066 PN 1048594
Your obese patients may have a serious sleep disorder OSA is a common condition, in which the upper airway repeatedly collapses during sleep. If left untreated, this condition has been associated with an increased risk of high blood pressure,
Screening for OSA before surgery If your obese patients are scheduled for surgery, you should be aware of the need to screen for OSA prior to surgery. In fact, the American Society of Anesthesiologists pre-operative guidelines indicate the need for screening patients pre-surgery for OSA.
Screening and diagnostic solutions There are a variety of tools available to screen or diagnose patients for OSA prior to surgery: • In-office questionnaires (e.g., the Berlin Questionnaire and Epworth Sleepiness Scale) • RUSleeping RTS (in-home, real-time apneic screener) • Polysomnogram (PSG) – done in a sleep lab
heart attack, depression, uncontrolled diabetes and stroke.
Questions to help assess a patient’s risk for OSA: 1. Do you snore?
Factors that may cause the airway to collapse during sleep:
2. Do you ever stop breathing during sleep?
• Extra tissue in the back of the airway such as large tonsils
3. Has anyone identified that you gasp, snort or pause your breathing while sleeping?
• Decrease in the tone of the muscles holding the airway open
4. Do you feel sleepy during the day? 5. Do you have a history of high blood pressure?
• The tongue falling back and closing off the airway
Some of the possible signs and symptoms of OSA:
If a patient answers yes to two or more of the above questions, follow-up with more detailed and objective testing performed in a sleep center or sleep lab.
If the results of the in-office questionnaires are positive, you can recommend objective sleep testing in the form of an in-lab sleep study or, if the patient qualifies, an in-home portable sleep test may be feasible.The sleep study (known as a polysomnogram) will diagnose whether the patient has OSA and indicate the best treatment for it. The benefits of treating OSA Clinical studies have shown that treatment of OSA may: • Lower blood pressure • Reduce daytime sleepiness and increase daytime energy
• Snoring, interrupted by pauses in breathing • Gasping or choking during sleep • Restless sleep • Excessive sleepiness or fatigue during the day • Large neck size (greater than 17” in men; greater than 16” in women) • Crowded airway • High blood pressure • Obesity
Philips Respironics offers a variety of screening questionnaires to help further assess patients at possible risk for OSA.
• Reduce the potential risk for heart attack, stroke and heart disease
Treatment of OSA Positive Airway Pressure (PAP) is the gold standard treatment for OSA. Continuous Positive Airway Pressure (CPAP) is the most commonly used PAP therapy. CPAP therapy provides a continuous flow of air pressure through the nose to prevent airway collapse, allowing the patient to breathe freely while sleeping. CPAP therapy is noninvasive and can alleviate the symptoms of OSA when used as prescribed.
Your obese patients may have a serious sleep disorder OSA is a common condition, in which the upper airway repeatedly collapses during sleep. If left untreated, this condition has been associated with an increased risk of high blood pressure,
Screening for OSA before surgery If your obese patients are scheduled for surgery, you should be aware of the need to screen for OSA prior to surgery. In fact, the American Society of Anesthesiologists pre-operative guidelines indicate the need for screening patients pre-surgery for OSA.
Screening and diagnostic solutions There are a variety of tools available to screen or diagnose patients for OSA prior to surgery: • In-office questionnaires (e.g., the Berlin Questionnaire and Epworth Sleepiness Scale) • RUSleeping RTS (in-home, real-time apneic screener) • Polysomnogram (PSG) – done in a sleep lab
heart attack, depression, uncontrolled diabetes and stroke.
Questions to help assess a patient’s risk for OSA: 1. Do you snore?
Factors that may cause the airway to collapse during sleep:
2. Do you ever stop breathing during sleep?
• Extra tissue in the back of the airway such as large tonsils
3. Has anyone identified that you gasp, snort or pause your breathing while sleeping?
• Decrease in the tone of the muscles holding the airway open
4. Do you feel sleepy during the day? 5. Do you have a history of high blood pressure?
• The tongue falling back and closing off the airway
Some of the possible signs and symptoms of OSA:
If a patient answers yes to two or more of the above questions, follow-up with more detailed and objective testing performed in a sleep center or sleep lab.
If the results of the in-office questionnaires are positive, you can recommend objective sleep testing in the form of an in-lab sleep study or, if the patient qualifies, an in-home portable sleep test may be feasible.The sleep study (known as a polysomnogram) will diagnose whether the patient has OSA and indicate the best treatment for it. The benefits of treating OSA Clinical studies have shown that treatment of OSA may: • Lower blood pressure • Reduce daytime sleepiness and increase daytime energy
• Snoring, interrupted by pauses in breathing • Gasping or choking during sleep • Restless sleep • Excessive sleepiness or fatigue during the day • Large neck size (greater than 17” in men; greater than 16” in women) • Crowded airway • High blood pressure • Obesity
Philips Respironics offers a variety of screening questionnaires to help further assess patients at possible risk for OSA.
• Reduce the potential risk for heart attack, stroke and heart disease
Treatment of OSA Positive Airway Pressure (PAP) is the gold standard treatment for OSA. Continuous Positive Airway Pressure (CPAP) is the most commonly used PAP therapy. CPAP therapy provides a continuous flow of air pressure through the nose to prevent airway collapse, allowing the patient to breathe freely while sleeping. CPAP therapy is noninvasive and can alleviate the symptoms of OSA when used as prescribed.
Your obese patients may have a serious sleep disorder OSA is a common condition, in which the upper airway repeatedly collapses during sleep. If left untreated, this condition has been associated with an increased risk of high blood pressure,
Screening for OSA before surgery If your obese patients are scheduled for surgery, you should be aware of the need to screen for OSA prior to surgery. In fact, the American Society of Anesthesiologists pre-operative guidelines indicate the need for screening patients pre-surgery for OSA.
Screening and diagnostic solutions There are a variety of tools available to screen or diagnose patients for OSA prior to surgery: • In-office questionnaires (e.g., the Berlin Questionnaire and Epworth Sleepiness Scale) • RUSleeping RTS (in-home, real-time apneic screener) • Polysomnogram (PSG) – done in a sleep lab
heart attack, depression, uncontrolled diabetes and stroke.
Questions to help assess a patient’s risk for OSA: 1. Do you snore?
Factors that may cause the airway to collapse during sleep:
2. Do you ever stop breathing during sleep?
• Extra tissue in the back of the airway such as large tonsils
3. Has anyone identified that you gasp, snort or pause your breathing while sleeping?
• Decrease in the tone of the muscles holding the airway open
4. Do you feel sleepy during the day? 5. Do you have a history of high blood pressure?
• The tongue falling back and closing off the airway
Some of the possible signs and symptoms of OSA:
If a patient answers yes to two or more of the above questions, follow-up with more detailed and objective testing performed in a sleep center or sleep lab.
If the results of the in-office questionnaires are positive, you can recommend objective sleep testing in the form of an in-lab sleep study or, if the patient qualifies, an in-home portable sleep test may be feasible.The sleep study (known as a polysomnogram) will diagnose whether the patient has OSA and indicate the best treatment for it. The benefits of treating OSA Clinical studies have shown that treatment of OSA may: • Lower blood pressure • Reduce daytime sleepiness and increase daytime energy
• Snoring, interrupted by pauses in breathing • Gasping or choking during sleep • Restless sleep • Excessive sleepiness or fatigue during the day • Large neck size (greater than 17” in men; greater than 16” in women) • Crowded airway • High blood pressure • Obesity
Philips Respironics offers a variety of screening questionnaires to help further assess patients at possible risk for OSA.
• Reduce the potential risk for heart attack, stroke and heart disease
Treatment of OSA Positive Airway Pressure (PAP) is the gold standard treatment for OSA. Continuous Positive Airway Pressure (CPAP) is the most commonly used PAP therapy. CPAP therapy provides a continuous flow of air pressure through the nose to prevent airway collapse, allowing the patient to breathe freely while sleeping. CPAP therapy is noninvasive and can alleviate the symptoms of OSA when used as prescribed.
Philips Healthcare is part of Royal Philips Electronics
Prevalence of OSA • As many as 5 to 10 percent of adults in the U.S. have OSA.1,2 • Nine percent of men and four percent of women have an apnea hypopnea index (AHI) greater than 15 (moderate OSA). • Prevalence of OSA is higher in the following ethnic groups3: – Asian – Hispanic women – African-American • 85 to 90 percent of people within the U.S. who may have OSA have not been identified.1
Many of the 20 million people in the U.S. suspected of having OSA may have an increased risk for other serious health conditions.
How to reach us www.philips.com/healthcare Fax: +31 40 27 64 887 Asia +852 2821 5888 Europe, Middle East,Africa +31 40 27 87246 Latin America +55 11 2125 0764
Philips Respironics 1010 Murry Ridge Lane Murrysville, PA 15668 Customer Service +1 724 387 4000 800 345 6443 (toll free) Respironics Europe, Middle East,Africa +33 1 47 52 30 00 Respironics Asia Pacific +852 3194 2280 www.philips.com/respironics
North America +1 425 487 7000 800 285 5585 (toll free, US only)
Cardiovascular disease
Stroke
Diabetes
For more information about Obstructive Sleep Apnea visit: www.sleepapnea.com
OSA 20 M overall
Help with a big problem How to screen for Obstructive Sleep Apnea (OSA) in your obese patients
Atrial fibrillation
Hypertension
© 2009 Koninklijke Philips Electronics N.V. All rights are reserved. 1 Young,T., et
al., NEJM 1993;328:1230-1235
2 Young,T., et
al., AJRCCM 2002;165:1217-1239
3 O’Connor, et
al., Sleep 2003;26(1):74-79
4 Hiestand, D.M., et
al., Chest 2006;130:780-786
Philips Healthcare reserves the right to make changes in specifications and/or to discontinue any product at any time without notice or obligation and will not be liable for any consequences resulting from the use of this publication. Geyer SB 1/22/09 MCI 4102066 PN 1048594
Philips Healthcare is part of Royal Philips Electronics
Prevalence of OSA • As many as 5 to 10 percent of adults in the U.S. have OSA.1,2 • Nine percent of men and four percent of women have an apnea hypopnea index (AHI) greater than 15 (moderate OSA). • Prevalence of OSA is higher in the following ethnic groups3: – Asian – Hispanic women – African-American • 85 to 90 percent of people within the U.S. who may have OSA have not been identified.1
Many of the 20 million people in the U.S. suspected of having OSA may have an increased risk for other serious health conditions.
How to reach us www.philips.com/healthcare Fax: +31 40 27 64 887 Asia +852 2821 5888 Europe, Middle East,Africa +31 40 27 87246 Latin America +55 11 2125 0764
Philips Respironics 1010 Murry Ridge Lane Murrysville, PA 15668 Customer Service +1 724 387 4000 800 345 6443 (toll free) Respironics Europe, Middle East,Africa +33 1 47 52 30 00 Respironics Asia Pacific +852 3194 2280 www.philips.com/respironics
North America +1 425 487 7000 800 285 5585 (toll free, US only)
Cardiovascular disease
Stroke
Diabetes
For more information about Obstructive Sleep Apnea visit: www.sleepapnea.com
OSA 20 M overall
Help with a big problem How to screen for Obstructive Sleep Apnea (OSA) in your obese patients
Atrial fibrillation
Hypertension
© 2009 Koninklijke Philips Electronics N.V. All rights are reserved. 1 Young,T., et
al., NEJM 1993;328:1230-1235
2 Young,T., et
al., AJRCCM 2002;165:1217-1239
3 O’Connor, et
al., Sleep 2003;26(1):74-79
4 Hiestand, D.M., et
al., Chest 2006;130:780-786
Philips Healthcare reserves the right to make changes in specifications and/or to discontinue any product at any time without notice or obligation and will not be liable for any consequences resulting from the use of this publication. Geyer SB 1/22/09 MCI 4102066 PN 1048594
